The Drugs Controller General of India has conducted emergency use of Hetero’s Tocilizumab for treatment of hospitalized adults suffering covid-19.
PTI reported, Hetero’s associate company Hetero Healthcare will market its biosimilar version of Tocilizumab under the brand name Tocira.
“This approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab. We will be working closely with the government to ensure equitable distribution.”, Hetero Group Chairman B Partha Saradhi Reddy said.
The drug Tocilizumab, which is a biosimilar version of ‘Roche’s Actemra’, would be available in the market by end of the September.